公开(公告)号：US20240309038A1

公开(公告)日：2024-09-19

申请号：US18259146

申请日：2021-12-22

申请人： GALECTO BIOTECH AB

发明人： Fredrik ZETTERBERG ,  Kristoffer PETERSON ,  Ulf NILSSON

IPC分类号： C07H19/04 ,  A61K31/7056 ,  A61K31/706

CPC分类号： C07H19/04 ,  A61K31/7056 ,  A61K31/706

摘要： A D-galactopyranose compound of formula (1)






wherein
the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of disorders relating to the binding of a galectin-3 to a ligand in a mammal. The disorders include inflammation; fibrosis; endometriosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; scleroderma; systemic sclerosis; septic shock; cancers; metastasising cancers; systemic lupus erythematosus; metabolic disorders; coagulopathies; cardiovascular disorders; heart disease; heart failure; and eye diseases; atherosclerosis; endocrine disorders; metabolic diseases; insulin resistance; obesity; Diastolic HF; atrophic diseases in the brain; disorders related to transplantation in organs; acute burn; acute inflammatory reaction; chronic acute skin graft rejection; chronic scarring; asthma and other interstitial lung diseases; Otosclerosis, mesothelioma; post-surgery disorders; toxin exposure disorders; Tissue injury; congenital hepatic fibrosis; hereditary fibrosing poikiloderma; liver disorders; and neurodegenerative disorders.

公开(公告)号：US20240239831A1

公开(公告)日：2024-07-18

申请号：US18598617

申请日：2024-03-07

申请人： The Queen's University of Belfast

发明人： Marie Migaud ,  Philip Redpath ,  Kerri Crossey ,  Mark Doherty

IPC分类号： C07H19/048 ,  C07H1/00 ,  C07H1/06 ,  C07H19/04

CPC分类号： C07H19/048 ,  C07H1/00 ,  C07H1/06 ,  C07H19/04 ,  Y02P20/582

摘要： Methods of preparing nicotinamide riboside and derivatives thereof, are described. In an aspect, the invention relates to a method of making a compound of formula (II), or a salt, or solvate thereof:






wherein n is 0 or 1;
Y is O or S;
m is 1;
R1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted primary or secondary amino, and substituted or unsubstituted azido; and
R2-R5 are each H.

公开(公告)号：US11981698B2

公开(公告)日：2024-05-14

申请号：US17736834

申请日：2022-05-04

申请人： The Queen's University of Belfast

发明人： Marie Migaud ,  Philip Redpath ,  Kerri Crossey ,  Mark Doherty

IPC分类号： C07H19/048 ,  C07H1/00 ,  C07H1/06 ,  C07H19/04

CPC分类号： C07H19/048 ,  C07H1/00 ,  C07H1/06 ,  C07H19/04 ,  Y02P20/582

摘要： Methods of preparing nicotinamide riboside and derivatives thereof, are described. In an aspect, the invention relates to a method of making a compound of formula (II), or a salt, or solvate thereof:






wherein n is 0 or 1;
Y is O or S;
m is 1;
R1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted primary or secondary amino, and substituted or unsubstituted azido; and
R2-R5 are each H.

公开(公告)号：US11667662B2

公开(公告)日：2023-06-06

申请号：US17206896

申请日：2021-03-19

申请人： ARCUS BIOSCIENCES, INC.

发明人： Laurent Pierre Paul Debien ,  Juan Carlos Jaen ,  Jaroslaw Kalisiak ,  Kenneth V. Lawson ,  Manmohan Reddy Leleti ,  Erick Allen Lindsey ,  Dillon Harding Miles ,  Eric Newcomb ,  Jay Patrick Powers ,  Brandon Reid Rosen ,  Ehesan Ui Sharif

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H19/23 ,  A61K31/7076 ,  C07H19/16 ,  C07H19/20 ,  C07H19/207 ,  C07F9/6561 ,  C07H19/04 ,  A61K31/706 ,  A61K45/06 ,  A61K31/7052 ,  A61K31/7064 ,  C07H19/14

CPC分类号： C07H19/23 ,  A61K31/70 ,  A61K31/706 ,  A61K31/7052 ,  A61K31/7064 ,  A61K31/7076 ,  A61K45/06 ,  C07F9/6561 ,  C07F9/65616 ,  C07H19/04 ,  C07H19/14 ,  C07H19/16 ,  C07H19/20 ,  C07H19/207 ,  A61K31/7076 ,  A61K2300/00 ,  A61K31/7064 ,  A61K2300/00 ,  A61K31/706 ,  A61K2300/00

摘要： Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

公开(公告)号：US20220290227A1

公开(公告)日：2022-09-15

申请号：US17576184

申请日：2022-01-14

申请人： The Trustees of Columbia University in the City of New York

发明人： Jingyue Ju ,  Dae Hyun Kim ,  Jia Guo ,  Qinglin Meng ,  Zengmin Li ,  Huanyan Cao

IPC分类号： C12Q1/6874 ,  C07H19/04 ,  C12Q1/6869 ,  C12Q1/6876

摘要： This invention provides a process for sequencing nucleic acids using 3′ modified deoxynucleotide analogues or 3′ modified deoxyinosine triphosphate analogues, and 3′ modified dideoxynucleotide analogues having a detectable marker attached thereto.

公开(公告)号：US20210198305A1

公开(公告)日：2021-07-01

申请号：US16618003

申请日：2018-06-01

申请人： WAVE LIFE SCIENCES LTD. ,  Pfizer Inc.

发明人： Chandra Vargeese ,  Naoki Iwamoto ,  David Charles Donnell Butler ,  Subramanian Marappan ,  Genliang Lu ,  Jason Jingxin Zhang ,  Vinod Vathipadiekal ,  Maria David Frank-Kamenetsky ,  Luciano Henrique Apponi ,  Hanna Maria Wisniewska ,  Xiayun Cheng ,  Young Jin Cho

IPC分类号： C07H17/04 ,  C07H19/04 ,  C12N15/113

摘要： Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.

公开(公告)号：US20200369639A1

公开(公告)日：2020-11-26

申请号：US16960347

申请日：2019-01-17

申请人： Synthena AG

发明人： Branislav Dugovic ,  Reto Bertolini

IPC分类号： C07D307/935 ,  C07H19/04 ,  C07H21/04 ,  C07D307/93

摘要： The present invention relates to a process for preparing tc-DNA nucleoside precursors, the resulting tc-DNA nucleosides, and oligonucleotides comprising such tc-DNA nucleosides. In an embodiment of the invention, the process includes use of a carbene precursor. In an embodiment, the invention includes processes for preparing a tc-DNA nucleoside precursor of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) or Formula (VI).

公开(公告)号：US20200325167A1

公开(公告)日：2020-10-15

申请号：US16916887

申请日：2020-06-30

申请人： Illumina Cambridge Limited

发明人： Xiaohai LIU ,  John MILTON ,  Silke RUEDIGER ,  Xiaolin WU

IPC分类号： C07H19/04 ,  C12Q1/6874 ,  C07H21/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H21/00 ,  C12Q1/6869 ,  C07H19/14

摘要： The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterised in that the cleavable linker contains a moiety selected from the group comprising: Formula (I) (wherein X is selected from the group comprising O, S, NH and NQ wherein Q is a C1-10 substituted or unsubstituted alkyl group, Y is selected from the group comprising O, S, NH and N(allyl), T is hydrogen or a C1-10 substituted or unsubstituted alkyl group and * indicates where the moiety is connected to the remainder of the nucleotide or nucleoside).

公开(公告)号：US10745728B1

公开(公告)日：2020-08-18

申请号：US16113766

申请日：2018-08-27

申请人： Steven A Benner ,  Hyo-Joong Kim ,  Zunyi Yang

发明人： Steven A Benner ,  Hyo-Joong Kim ,  Zunyi Yang

IPC分类号： C07H19/00 ,  C07H21/00 ,  C12P19/34 ,  C12Q1/686 ,  C07H19/04 ,  C07H21/02 ,  C07H21/04

摘要： This invention relates to the use of analogs of purines that have two tautomeric forms, one formally complementary to thymidine, the other formally complementary to cytidine, and analogs of pyrimidines that have two tautomeric forms, one formally complementary to guanosine, the other formally complementary to adenosine. These uses include the polymerase chain reaction amplification of targets having polymorphisms in primer binding sites and ligation.

公开(公告)号：US10509041B2

公开(公告)日：2019-12-17

申请号：US15956897

申请日：2018-04-19

申请人： HIROSAKI UNIVERSITY

发明人： Katsuya Yamada ,  Ayako Sasaki ,  Tadashi Teshima ,  Toshihiro Yamamoto ,  Yuji Otsuka

IPC分类号： G01N33/66 ,  C07H17/075 ,  C07H19/04 ,  A61K49/00 ,  A61K51/04 ,  C07H17/02 ,  G01N33/574 ,  G01N33/58

摘要： Provided is a glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Also provided are an imaging agent and an imaging method for a cell or intracellular molecule using said glucose derivative. Further provided is a method for detecting cancer cells with good accuracy using said glucose derivative and an imaging agent to be used in said method. More specifically provided are D-glucose derivatives and L-glucose derivatives in which glucose is bound to the 7-position of a fluorescent molecular group with a coumarin backbone or a quinolone backbone. Also provided are a cell imaging agent and imaging method using the derivative. A cancer cell imaging agent and imaging method using the L-glucose derivative is also provided. G is a group selected from formulas (G1)-(G4) below.